Published in Mayo Clin Proc on July 01, 2009
Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis. Osteoporos Int (2013) 2.05
Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. Calcif Tissue Int (2011) 1.50
The effects of differing resistance training modes on the preservation of bone mineral density in postmenopausal women: a meta-analysis. Osteoporos Int (2015) 1.47
Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management. ScientificWorldJournal (2012) 1.40
Polypharmacy patterns: unravelling systematic associations between prescribed medications. PLoS One (2013) 0.93
Consequences of irradiation on bone and marrow phenotypes, and its relation to disruption of hematopoietic precursors. Bone (2014) 0.87
Perspectives of pharmacological treatment in otosclerosis. Eur Arch Otorhinolaryngol (2012) 0.83
Increased treatment persistence and its determinants in women with osteoporosis with prior fracture compared to those without fracture. Osteoporos Int (2015) 0.82
Zoledronic acid: clinical utility and patient considerations in osteoporosis and low bone mass. Drug Des Devel Ther (2010) 0.81
GRAND-4: the German retrospective analysis of long-term persistence in women with osteoporosis treated with bisphosphonates or denosumab. Osteoporos Int (2016) 0.79
Developing an evidence-based clinical pathway for the assessment, diagnosis and management of acute Charcot Neuro-Arthropathy: a systematic review. J Foot Ankle Res (2013) 0.79
Paget's Disease of Bone: A Review of Epidemiology, Pathophysiology and Management. Ther Adv Musculoskelet Dis (2009) 0.79
Hovenia dulcis Thunb extract and its ingredient methyl vanillate activate Wnt/β-catenin pathway and increase bone mass in growing or ovariectomized mice. PLoS One (2014) 0.79
Complications of pamidronate therapy in paediatric osteoporosis. J Child Orthop (2012) 0.79
Advances in Controlled Drug Delivery for Treatment of Osteoporosis. Curr Osteoporos Rep (2016) 0.77
Efficacy and safety of bazedoxifene for postmenopausal osteoporosis. Clin Interv Aging (2011) 0.77
Association of teriparatide adherence and persistence with clinical and economic outcomes in Medicare Part D recipients: a retrospective cohort study. BMC Musculoskelet Disord (2013) 0.77
Additive effects of antiresorptive agents and exercise on lumbar spine bone mineral density in adults with low bone mass: a meta-analysis. Osteoporos Int (2014) 0.76
Euodia sutchuenensis Dode extract stimulates osteoblast differentiation via Wnt/β-catenin pathway activation. Exp Mol Med (2015) 0.76
Optimizing screening for osteoporosis in patients with fragility hip fracture. Clin Orthop Relat Res (2011) 0.76
Rapid phenotyping of knockout mice to identify genetic determinants of bone strength. J Endocrinol (2016) 0.75
WSS25, a sulfated polysaccharide, inhibits RANKL-induced mouse osteoclast formation by blocking SMAD/ID1 signaling. Acta Pharmacol Sin (2015) 0.75
Osthole Promotes Endochondral Ossification and Accelerates Fracture Healing in Mice. Calcif Tissue Int (2016) 0.75
Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis-reply to Pazianas and Abrahamsen. Osteoporos Int (2014) 0.75
Protocol for a randomized controlled trial to compare bone-loading exercises with risedronate for preventing bone loss in osteopenic postmenopausal women. BMC Womens Health (2016) 0.75
Efficacy of Intraperitoneal Administration of PEGylated NELL-1 for Bone Formation. Biores Open Access (2016) 0.75
Is GERD a Factor in Osteonecrosis of the Jaw? Evidence of Pathology Linked to G6PD Deficiency and Sulfomucins. Dis Markers (2016) 0.75
Gender- and age-related treatment compliance in patients with osteoporosis in Germany. Patient Prefer Adherence (2016) 0.75
Maxilla Osteonecrosis: a differential diagnosis in patients with metastatic cancer on bisphosphonates. J Case Rep Med (2016) 0.75
We need a break: Bisphosphonates. J Clin Orthop Trauma (2013) 0.75
Bisphosphonates and cardiac electrophysiology: should the red flag be raised higher? J Cardiovasc Electrophysiol (2014) 0.75
An optical assay of the transport activity of ClC-7. Sci Rep (2013) 0.75
Treadmill running exercise prevents senile osteoporosis and upregulates the Wnt signaling pathway in SAMP6 mice. Oncotarget (2016) 0.75
Postmenopausal Breast Cancer, Aromatase Inhibitors, and Bone Health: What the Surgeon Should Know. World J Surg (2016) 0.75
Acceleration of osteoblast differentiation by a novel osteogenic compound, DMP-PYT, through activation of both the BMP and Wnt pathways. Sci Rep (2017) 0.75
Development of Bone Targeting Drugs. Int J Mol Sci (2017) 0.75
Examination of the foreign body response to biomaterials by nonlinear intravital microscopy. Nat Biomed Eng (2016) 0.75
Factors associated with high 24-month persistence with denosumab: results of a real-world, non-interventional study of women with postmenopausal osteoporosis in Germany, Austria, Greece, and Belgium. Arch Osteoporos (2017) 0.75
Vitamin D deficiency. N Engl J Med (2007) 59.34
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med (2007) 18.27
Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA (2006) 12.47
Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med (2004) 8.86
Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab (2004) 8.36
Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med (2006) 7.46
Reports of esophageal cancer with oral bisphosphonate use. N Engl J Med (2009) 7.09
Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res (2007) 6.76
Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med (2008) 4.81
Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg (2007) 4.26
Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res (2004) 4.04
Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum (2006) 2.82
Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res (2009) 2.65
Alendronate and atrial fibrillation. N Engl J Med (2007) 2.00
Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. Leuk Lymphoma (2008) 1.85
Vitamin D status in relation to one-year risk of recurrent falling in older men and women. J Clin Endocrinol Metab (2006) 1.58
Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ (2008) 1.54
Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis. Clin Pharmacokinet (2005) 1.37
Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner Res (1997) 1.35
Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6. J Interferon Cytokine Res (2003) 1.34
Yearly zoledronic acid in postmenopausal osteoporosis. N Engl J Med (2007) 1.29
Vitamin D status and response to treatment in post-menopausal osteoporosis. Osteoporos Int (2008) 1.26
Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res (2002) 1.22
More on atypical fractures of the femoral diaphysis. N Engl J Med (2008) 1.21
Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study. Mayo Clin Proc (2002) 1.19
The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women. J Clin Endocrinol Metab (2008) 1.14
Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw. J Bone Miner Res (2009) 1.04
Atypical femoral fractures, bisphosphonates, and adult hypophosphatasia. J Bone Miner Res (2009) 0.92
Effects of intravenous zoledronate on bone turnover and BMD persist for at least 24 months. J Bone Miner Res (2008) 0.87
beta-arrestin-dependent, G protein-independent ERK1/2 activation by the beta2 adrenergic receptor. J Biol Chem (2005) 4.91
A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. Proc Natl Acad Sci U S A (2007) 3.82
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc (2013) 2.59
Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab (2012) 1.96
In vivo assessment of bone quality in postmenopausal women with type 2 diabetes. J Bone Miner Res (2014) 1.90
Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease. Blood (2011) 1.88
Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia. Blood (2010) 1.83
Vitamin D deficiency in adults: when to test and how to treat. Mayo Clin Proc (2010) 1.60
Altered cortical microarchitecture in patients with monoclonal gammopathy of undetermined significance. Blood (2013) 1.42
Hypovitaminosis D in psychiatric inpatients: clinical correlation with depressive symptoms, cognitive impairment, and prescribing practices. Psychosomatics (2012) 1.41
Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis. J Clin Endocrinol Metab (2012) 1.37
International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. J Clin Oncol (2013) 1.19
Monoclonal gammopathy of undetermined significance: a consensus statement. Br J Haematol (2010) 1.14
Does this woman have osteoporosis? JAMA (2004) 1.00
Impact of vitamin D deficiency on the clinical presentation and prognosis of patients with newly diagnosed multiple myeloma. Am J Hematol (2009) 0.96
Clinical spectrum of hypophosphatasia diagnosed in adults. Bone (2013) 0.95
Potential role for therapies targeting DKK1, LRP5, and serotonin in the treatment of osteoporosis. Curr Osteoporos Rep (2012) 0.92
Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res (2016) 0.91
Relationship of adiposity to bone volumetric density and microstructure in men and women across the adult lifespan. Bone (2013) 0.89
Early life sun exposure, vitamin D-related gene variants, and risk of non-Hodgkin lymphoma. Cancer Causes Control (2012) 0.89
Effects of estrogen on bone mRNA levels of sclerostin and other genes relevant to bone metabolism in postmenopausal women. J Clin Endocrinol Metab (2013) 0.88
Vitamin D insufficiency in myeloproliferative neoplasms and myelodysplastic syndromes: clinical correlates and prognostic studies. Am J Hematol (2011) 0.88
Cargo-sorting signals promote polymerization of adaptor protein-1 in an Arf-1.GTP-independent manner. Arch Biochem Biophys (2008) 0.79
Vitamin D in the cancer patient. Curr Opin Support Palliat Care (2013) 0.78
Bone-targeted replacement therapy for hypophosphatasia. J Bone Miner Res (2008) 0.75
A case of endocrinologic crisis in a woman with subacute blindness. Neurology (2010) 0.75
Corrigendum: Targeting cellular senescence prevents age-related bone loss in mice. Nat Med (2017) 0.75